Start Your Search
P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)
- Event: WCLC 2015
- Type: Poster
- Track: Treatment of Advanced Diseases - NSCLC
- Presentations: 1
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
P1.01-054 - To Analyse the Efficacy and Toxicity Profile of Continuation Maintenance Pemetrexed in Advanced NSCLC: An Indian Data (ID 1073)
09:30 - 17:00 | Author(s): K.D. Choydhary
Continuation maintenance therapy with pemetrexed has been proved to be well tolerated ,offers an overall survival benefit and reduced risk of disease progression in Phase III Paramount trial. Based on same it is approved as a category 1 recommendation for patients with nonsquamous advanced lung cancer, who do not progress after pemetrexed plus platinum induction regimen. However there is lack of data from Indian subcontinent. Here we report the data from a tertiary care cancer centre in North India
- In all 280 patients were registered as advanced non squamous lung cancer(stage IV) between JAN 14 to DEC 14. Subsequently 96 patients received pemetrexed plus platinum based initial chemotherapy. 46 patients with no disease progression and ECOG PS 0 or 1 received maintenance pemetrexed (500 mg/m[2 on] day 1 of 21 day cycles). Statistical tests were applied to calculate progression free survival. Toxicity profile was evaluated
The mean number of maintenance cycles was 9.5. Pemetrexed maintenance therapy resulted in progression free survival (PFS) of 5.4 months. PFS on pemetrexed was consistent for all patient subgroups, including induction response: complete/partial responders (n-24 ) and stable disease (n-22 ). 3 patients developed grade 3 or 4 toxicity as to cause a delay in cycles.2 patients also developed renal dysfunction during maintenance therapy. 7 patients continue to receive pemetrexed maintenance till date.
Pemetrexed continuation maintenance therapy is well-tolerated and offers benefits consistent with Paramount trial, demonstrating that it is an efficacious treatment strategy for Indian patients with advanced nonsquamous NSCLC and good performance status who do not progress during pemetrexed-platinum induction therapy
Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.